Formulation and manufacturing process for Coenzyme Q10 soft gel capsules

Abstract

A soft gelatine capsule formulation improved manufacturing of Coenzyme Q10, comprising Coenzyme Q10 in a thixotropic gelatine carrier capable of admixing without heating with Coenzyme Q10, and capable of keeping Coenzyme Q10 in suspension at ambient temperature.

Description

[0001] This is a Continuation of U.S. application Ser. No. 10 / 368,260 filed on Feb. 18, 2003, which is a Continuation-In-Part of U.S. application Ser. No. 09 / 873,156 which was filed Jun. 1, 2001, now abandoned, that in turn claims priority benefit of U.S. Provisional Application Ser. No. 60 / 263,953 filed Jan. 24, 201, the contents of which are incorporated herein in their entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] This invention relates to a composition and process of manufacturing Coenzyme Q10 with improved human absorption characteristics in a thixotropic gelatin carrier capable of admixing without heating the Coenzyme Q10, and capable of suspending Coenzyme Q10 in a uniform dispersion. [0004] 2. Background go of the Invention [0005] Coenzyme Q10 (CoQ10 or Ubiquinone) is a large molecular weight (863.63 grams) lipid compound that is produced in the liver and perhaps other body organs. The total human body content is estimated to be 1.4 to 1.8 gram...

AI Technical Summary

Benefits of technology

[0010] According to the present invention, a preferred soft gel formulation includes Coenzyme Q10, Vitamin E (mixed tocopherols) added as a functional antioxidant, and a thixatropic gelatin carrier which has the ability of enhancing the solubility and stability of the active ingredient and provides for better absorption thereof in humans. An additional ingredient, an antioxidant, either from natural or synthetic sources, can be added in order to prepare a potent combination antioxidant formulation. The preferred soft gel Coenzyme Q10 formulation is administered twice a day in dosages of about 30 mg, thereby reducing the Coenzyme Q10 cost while producing the desired retained Coenzyme Q10 in the human body.

Problems solved by technology

These numbers are currently being studied and endogenous CoQ10 synthesis may be significantly deficient in the elderly.

If CoQ10 is used as an antioxidant, it gets oxidized and is no longer available to provide electrons and function in the synthesis of ATP.

Under conditions of high metabolic stress, endogenous sources may become inadequate to meet the body's CoQ10 requirement for ATP synthesis.

An appropriate CoQ10 dosage for a normal individual compared to the dosage necessary for a diseased individual has been difficult to ascertain.

In the past 15 years, it has become generally accepted that poor intestinal absorption of certain CoQ10 formulations limits their effective use.

However, intestinal absorption data, collected under near basal conditions, which compare CoQ10 alone in oil with dry powder CoQ10, are inconclusive.